Helix BioPharma Corp
HBP
Company Profile
Business description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.
Contact
40 Temperance Street
Suite 2700, Bay Adelaide Centre - North Tower
TorontoONM5H0B4
CANT: +1 604 684-2181
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,369.30 | 4.70 | -0.06% |
CAC 40 | 7,698.83 | 29.10 | -0.38% |
DAX 40 | 23,168.26 | 176.28 | -0.76% |
Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
FTSE 100 | 8,588.50 | 7.85 | -0.09% |
HKSE | 22,662.71 | 158.03 | 0.70% |
NASDAQ | 17,844.24 | 133.49 | -0.74% |
Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
NZX 50 Index | 12,421.09 | 0.16 | -0.00% |
S&P 500 | 5,650.38 | 36.29 | -0.64% |
S&P/ASX 200 | 8,151.40 | 6.40 | -0.08% |
SSE Composite Index | 3,316.11 | 37.08 | 1.13% |